

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BBB	BS	5,250,414	A	Schwab et al	10-05-1993	—
	BT	5,684,133	A	Schwab et al	11-04-1997	—
	BU	5,114,721	A	Cohen et al	05-19-1992	—
	BV	5,633,426	A	Namikawa et al	05-27-1997	—
	BW	5,858,364	A	Weiner et al	01-12-1999	—
BBB	BX	6,319,892	B1	Gold et al	11-20-2001	—

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
BBB	BY	WO	96/16085	A1	Neurocrine Biosciences Inc. & Stanford Univ Medical Center	05-30-1996	—	—
	BZ	WO	93/00427	A2	Erziehungsdirektion Cant. Zurich	01-07-1993	—	—
	CA	WO	00/31235	A1/3	Schwab et al	06-02-2000	—	—
	CB	WO	00/60083	A1	Chiron Corporation	10-12-2000	—	—
BBB	CC	WO	01/36631	A1	Smithkline Beechm PLC	05-25-2001	—	—

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BBB	CD	BECKER et al, "Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia", <u>Proc Natl Acad Sci USA</u> 94(20):10873-10878 (1997)	—
	CE	BERKOW et al (Eds), <u>The Merck Manual of Diagnosis and Therapy</u> 16 th Ed., Merck Research Laboratories, Rahway, NJ, pp. 110, 111, 412, 413, 1452-1459, 1488-1490, 1510, 1511, and 1518-1523 (1992)	—
	CF	BRADBURY et al, "NT-3, but not BDNF, prevents atrophy and death of axotomized spinal cord projection neurons", <u>Eur J Neurosci</u> 10(10):3058-3068 (1998)	—
BBB	CG	BROD et al, "Autologous T-T Cell Activation Mediated by Cell Adhesion Molecules", <u>FASEB J</u> 3(3):A514 (1989)	—

Examiner
Signature

Bridget C. Bunner

Date
Considered

9/15/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BBB	CH	COHEN et al, "Autoimmune maintenance and neuroprotection of the central nervous system", <u>J Neuroimmunol</u> 100(1-2):111-114 (1999)	-
	CI	ENOCH et al, "Different functional changes recorded in open angle glaucoma and anterior ischemic optic neuropathy", <u>Doc Ophthalmol</u> 50(1):169-184 (1980)	-
	CJ	GEORGE et al, "Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels", <u>J Neurosci</u> 15(10):6445-6452 (1995)	-
	CK	HAUBEN et al, "Autoimmune T cells as potential neuroprotective therapy for spinal cord injury", <u>Lancet</u> 355(9200):286-287 (2000)	-
	CL	HAUBEN et al, "Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion", <u>J Neurosci</u> 20(17):6421-6430 (2000)	-
	CM	HAY RJ, "Human cells and cell cultures: availability, authentication and future prospects", <u>Hum Cell</u> 9(3):143-152 (1996)	-
	CN	JACKOWSKI A, "Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer", <u>Br J Neurosurg</u> 9(3):303-317 (1995)	-
	CO	KANDEL et al (Eds.), <u>Principles of Neural Science</u> , Elsevier Science Publishing Co., Inc. (New York, NY), pp. 977-982	-
	CP	LI et al, "β-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities", <u>Proc Natl Acad Sci USA</u> 77(6):3211-3214 (1980)	-
	CQ	LIUZZI et al, "Peripheral nerve regeneration", <u>Neurosurg Clin N Am</u> 2(1):31-42 (1991)	-
	CR	LOHSE et al, "Control of Experimental Autoimmune Encephalomyelitis by T Cells Responding to Activated T Cells", <u>Science</u> 244:820-822 (1989)	-
BBB	CS	LOHSE et al, "Inhibition of the mixed lymphocyte reaction by T cell vaccination", <u>Eur J Immunol</u> 20:2521-2524 (1990)	-

Examiner
Signature

Bridget E Bunner

Date
Considered

9/15/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of 4

Complete if Known

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BOB	CT	LOHSE et al, "Induction of the anti-ergotypic response", <u>International Immunology</u> 4(5):533-539 (1993)	-
	CU	MOALEM et al, "Autoimmune T cells retard the loss of function in injured rat optic nerves", <u>J Neuroimmunol</u> 106(1-2):189-197 (2000)	-
	CV	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease", <u>Neurology</u> 39(9) 1159-1165 (1989)	-
	CW	PAN et al, "Tumor necrosis factor-alpha: a neuromodulator in the CNS", <u>Neurosci Biobehav Rev</u> 21(5):603-613 (1997)	-
	CX	PLATA SALAMAN C, "Epidermal growth factor and the nervous system", <u>Peptides</u> 12(3):653-663 (1991)	-
	CY	PETROVICH et al, "Pentoxifylline suppression of TNF- α mediated axonal degeneration in the rabbit optic nerve", <u>Neurol Res</u> 19(5):551-554 (1997)	-
	CZ	POSER CM, "The role of trauma in the pathogenesis of multiple sclerosis a review", <u>Clin Neurol Neurosurg</u> 96(2):103-110 (1994)	-
	DA	SKOLNICK et al, "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <u>Trends Biotechnol</u> 18(1):34-39 (2000)	-
	DB	TANABE et al, "Diversity and pattern in the developing spinal cord", <u>Science</u> 274(5290):1115-1123 (1996)	-
	DC	WANG et al, "Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy", <u>J Neuropathol Exp Neurol</u> 59(7):599-606 (2000)	-
	DD	YÜCEL et al, "Histomorphometric analysis of optic nerve changes in experimental glaucoma", <u>J Glaucoma</u> 8(1):38-45 (1999)	-
BOB	DE	YUEN et al, "Immunoregulatory CD8 ⁺ Cells Recognize Antigen-Activated CD4 ⁺ Cells in Myasthenia Gravis Patients and in Healthy Controls", <u>J Immunol</u> 154(3):1508-1520 (1995)	-

Examiner
Signature

Bridget E. Bunner

Date
Considered

9/15/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	09/893,348
Filing Date	October 31, 2001
First Named Inventor	Michal EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	EIS-SCHWARTZ=2A

Sheet	4	of	4
-------	---	----	---

[illegible]

RECEIVED

JAN 16 2003

TECH CENTER 1600/2900

Examiner
Signature

Bridget C. Gunner

Date
Considered

9/15/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.